Drug Patents owned by Gilead

1. List of Letairis drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8377933 GILEAD Method for treating a pulmonary hypertension condition
Dec, 2027

(4 years from now)

US9474752 GILEAD Method for treating a pulmonary hypertension condition
Dec, 2027

(4 years from now)

US9549926 GILEAD Compositions and methods of treating pulmonary hypertension
Oct, 2031

(8 years from now)

Drugs and Companies using AMBRISENTAN ingredient

Market Authorisation Date: 15 June, 2007

Treatment: For the treatment of pulmonary hypertension (pah) in combination with tadalafil; For the treatment of pulmonary arterial hypertension (pah) in combination with tadalafil, wherein the weight ratio of ambrisentan to tadalafil is about 1:2 to about 1:3

Dosage: TABLET;ORAL

How can I launch a generic of LETAIRIS before it's patent expiration?
More Information on Dosage

LETAIRIS family patents

17

United States

4

European Union

3

Australia

3

Japan

3

Hungary

2

Korea, Republic of

2

Poland

2

Spain

2

Cyprus

2

Slovenia

2

Portugal

2

EA

2

New Zealand

2

Canada

2

Denmark

1

Hong Kong

1

RS

1

Brazil

1

Lithuania

1

Luxembourg

1

Mexico

1

Argentina

1

South Africa

1

China

1

Croatia

1

Taiwan, Province of China

2. List of Truvada drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8592397 GILEAD Compositions and methods for combination antiviral therapy
Jan, 2024

(11 months from now)

US9457036 GILEAD Compositions and methods for combination antiviral therapy
Jan, 2024

(11 months from now)

US9744181 GILEAD Compositions and methods for combination antiviral therapy
Jan, 2024

(11 months from now)

US8716264 GILEAD Compositions and methods for combination antiviral therapy
Jan, 2024

(11 months from now)

Drugs and Companies using EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE ingredient

Market Authorisation Date: 02 August, 2004

Treatment: Treatment of hiv; Method of treatment of adults infected with hiv-1; Treatment of hiv-1 infection in pediatric patients 12 years of age and older; Treatment of hiv infection

Dosage: TABLET;ORAL

How can I launch a generic of TRUVADA before it's patent expiration?
More Information on Dosage

TRUVADA family patents

15

United States

8

Japan

4

Norway

4

European Union

3

Korea, Republic of

3

Australia

3

Argentina

3

China

2

Poland

2

EA

2

Croatia

2

Canada

2

Taiwan, Province of China

1

Austria

1

Hong Kong

1

Brazil

1

AP

1

Ukraine

1

Spain

1

Germany

1

Israel

1

Cyprus

1

Mexico

1

Slovenia

1

South Africa

1

Portugal

1

Iceland

1

New Zealand

1

Denmark

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic

Other things you might be interested in